Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUDCA add-on therapy in amyotrophic lateral sclerosis (ALS)
2018-002722-22Phase 3Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tauroursodeoxycholic acid in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Humanitas Research Hospital. Primary endpoint: Responder rate based on ALSFRS-R slope improvement. Started Feb 2019; status: completed.
02
Drugs
tauroursodeoxycholic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2018-002722-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002722-22.